Table 1 Patient and disease characteristics of patients who failed to achieve ANC recovery by day +30.
Variables | Modalities | N = 141 |
|---|---|---|
Age at HSCT | Median (range)[IQR] | 56.4 (18.2–74.1) |
[46.2–64.3] | ||
Patient sex | Female | 54 (38.3) |
Male | 87 (61.7) | |
Year of HSCT | Median (range)[IQR] | 2020 (2011–2022) |
[2017–2021] | ||
Median FU (y) | − | 1.1 [1–1.7] |
ELN2022 cytogenetic risk | Favorable | 8 (7.3) |
Adverse | 34 (30.9) | |
Intermediate | 68 (61.8) | |
Missing | 31 | |
Disease status at HSCT | CR1 | 92 (65.7) |
CR2 | 12 (8.6) | |
CR ≥ 3 | 1 (0.7) | |
PIF/Rel/Prog | 30 (21.4) | |
Other | 5 (3.6) | |
Missing | 1 | |
KPS | <90 | 49 (35.8) |
≥90 | 88 (64.2) | |
Missing | 4 | |
Female to male | No | 118 (83.7) |
Yes | 23 (16.3) | |
Donor type | UD 10/10 | 72 (51) |
UD 9/10 | 48 (34) | |
UD 8/10 | 4 (2.8) | |
UD (missing HLA) | 17 (12.1) | |
Patient CMV | Negative | 27 (19.6) |
Positive | 111 (80.4) | |
Missing | 3 | |
Donor CMV | Negative | 60 (42.9) |
Positive | 80 (57.1) | |
Missing | 1 | |
Source of cells | BM | 15 (10.6) |
PB | 126 (89.4) | |
Myeloablative conditioning | No | 78 (55.7) |
Yes | 62 (44.3) | |
Missing | 1 | |
In vivo TCD | No | 119 (84.4) |
ATG | 21 (14.9) | |
Campath | 1 (0.7) |
